Article info

Download PDFPDF
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Authors

  1. Correspondence to Professor Sandro Pignata, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli 80131, Italy; s.pignata{at}istitutotumori.na.it
View Full Text

Citation

Daniele G, Raspagliesi F, Scambia G, et al
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Publication history

  • Received February 1, 2021
  • Revision received March 30, 2021
  • Accepted March 31, 2021
  • First published April 30, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.